4.5 Review

Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 88, Issue 12, Pages 4965-4984

Publisher

WILEY
DOI: 10.1111/bcp.14958

Keywords

developmental pharmacology; drug development; paediatrics

Funding

  1. Clinical Research and Education Council of the University Hospitals Leuven
  2. Young Taishan Scholars Program of Shandong Province [2017ZX09304029-002]
  3. National Science and Technology Major Projects for Major New Drugs Innovation and Development [2017ZX09304029-002]
  4. Operational Program Research, Development and Education [CZ.02.2.69/0.0/0.0/16_027/0008495]
  5. Innovative Medicines Initiative 2 Joint Undertaking [777389]
  6. European Union's Horizon 2020 research and innovation programme
  7. EFPIA
  8. GSK
  9. Pfizer

Ask authors/readers for more resources

Developmental pharmacology focuses on the impact of maturation on drug metabolism and effects in pediatric patients, providing insights into drug development strategies and highlighting the importance of considering developmental pharmacodynamics. This paper summarizes current knowledge, identifies remaining gaps, and suggests innovative approaches for studying drug disposition and effects in children.
Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PK) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to pharmaceutical companies, regulatory agencies and academicians on how to incorporate the latest knowledge regarding developmental pharmacology and innovative techniques into neonatal and paediatric drug development. Biological aspects of drug absorption, distribution, metabolism and excretion throughout development are summarized. Although this area made enormous progress during the last two decades, remaining knowledge gaps were identified. Minimal risk and burden designs allow for optimally informative but minimally invasive PK sampling, while concomitant profiling of drug metabolites may provide additional insight in the unique PK behaviour in children. Furthermore, developmental PD needs to be considered during drug development, which is illustrated by disease- and/or target organ-specific examples. Identifying and testing PD targets and effects in special populations, and application of age- and/or population-specific assessment tools are discussed. Drug development plans also need to incorporate innovative techniques such as preclinical models to study therapeutic strategies, and shift from sequential enrolment of subgroups, to more rational designs. To stimulate appropriate research plans, illustrations of specific PK/PD-related as well as drug safety-related challenges during drug development are provided. The suggestions made in this joint paper of the Innovative Medicines Initiative conect4children Expert group on Developmental Pharmacology and the European Society for Developmental, Perinatal and Paediatric Pharmacology, should facilitate all those involved in drug development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available